Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...

Merck (MRK) stock returned 78.7% in the twelve months to October 21, 2026, against 16.5% for the S&P 500. Over that year, ...

TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...

The $20-per-ADS all-cash acquisition agreement follows Phase 2 progress for Divesiran and is expected to close in the first ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight ...